期刊文献+

新型表皮生长因子受体抑制剂——西妥昔单抗 被引量:12

A New Epidermal Growth Factor Receptor Inhibitor-Cetuximab
在线阅读 下载PDF
导出
摘要 西妥昔单抗是一种嵌合的单克隆抗体,它选择性地与表皮生长因子受体〔存在于正常细胞(皮肤和毛发细胞)和许多肿瘤细胞(如结肠癌、直肠癌)的表面〕特异性地结合,从而抑制肿瘤细胞的增殖,诱导肿瘤细胞凋亡。本文综述了西妥昔单抗的药理作用及临床评价。 Cetuximab is a chimeric monoclonal antibody highly selective to bind the epidermal growth factor receptor ( EGFR), which is found on the surface of normal cells ( such skin and hair cells) and some types of cancer cells including colorectal cancer. Thus, the proliferation of the tumor cells are inhibited and apoptosis of tumor cells by inducing, The pharmacologic actions of cetuximab and its clinical evaluation are reviewed in this paper.
出处 《中国全科医学》 CAS CSCD 2006年第4期317-318,共2页 Chinese General Practice
关键词 西妥昔单抗 受体 表皮生长因子 药理作用 临床评价 Cetuximab Receptor, epidermal growth factor (EGFR) Pharmacological actions Clinic evaluation
  • 相关文献

参考文献9

  • 1Baselga J.The EGFR as a target for anticancer therapy-focus on cetuximab[J].Eur J Cancer,2001,37(4):16-22.
  • 2Paul M,Harari PM,Huang SM.Headneck cancer as a clinical mode for molecular targeting of therapy:combing ECFG blockade with radiation[J].Int J Rediat Oncol Bid Phys,2001,49(2):427-433.
  • 3Delbaldo C,Pierga JY,Dieras V,et al.Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor(EGFR)-expressing advanced solid tumours.Results of a phase I study[abstract no.552][J].Eur J Cancer,2003,1 (5):167.
  • 4Folprecht G,Lutz MP,Schoeffski P,et al.Pharmacokinetic(PK) evaluation of cetuximab in combination with weekly irinotecan (CPT-11) and 24h infusional 5-FU/folinic acid (FA) as first line treatment in patients (pts) with epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer(MCRC)[abstract no.890][J].Proc Am Soc Clin Oncol,2003,222.
  • 5Cunningham D,Humblet Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med.2004,351(4):337-345..
  • 6Erbitux[EB/OL].http://www.fda.gov/cder/foi/label/2004/125084lbl.pdf,2005-02-16/2005-02-16.
  • 7Xiong HQ,Rosenberg A,LoBuglio A,et al.Cetuximab,a monoclonal antibody targeting the epidermal growth factor receptor,in combination with gemcitabine for advanced pancreatic cancer:a multicenter phase II Trial[J].J Clin Oncol,2004,22(13):2610-2616.
  • 8Saltz LB,Meropol NJ,Loehrer PJ Sr,et al.Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J].J Clin Oncol,2004,22(7):1201-1208.
  • 9Rubin MS,Shin DM,Pasmantier M,et al.Monoclonal antibody IMC-225,an anti-epidermal growth factor receptor,for patients with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens[J].Proc Am Soc Clin Oncol,2000,19:231.

同被引文献125

引证文献12

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部